What is Nucleai?
Nucleai is a pioneering force in AI-powered precision oncology, dedicated to revolutionizing biomarker discovery and treatment decision-making. The company's advanced platform harnesses unique tissue datasets to generate profound insights into cancer biology. This capability is instrumental in enhancing the efficacy of clinical trials and ultimately improving patient care pathways. Nucleai actively collaborates with leading pharmaceutical entities, offering its research platform for internal utilization and engaging in joint biomarker discovery projects.
How much funding has Nucleai raised?
Nucleai has raised a total of $53.5M across 3 funding rounds:
Series A
$6.5M
Series B
$33M
Other Financing Round
$14M
Series A (2020): $6.5M with participation from Debiopharm Group companies, Vertex Ventures, and Grove Ventures Capital
Series B (2022): $33M led by Sanofi Ventures and Section 32
Other Financing Round (2024): $14M supported by Merck Ventures
Key Investors in Nucleai
Merck Ventures
M Ventures is the strategic, corporate venture capital arm of Merck, focused on investing in innovative technologies with the potential to significantly impact Merck's core business areas. They invest globally in transformational ideas and take an active role in their portfolio companies.
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi, particularly in oncology and immunology.
Section 32
S32 | Venture Beyond is a venture capital firm that focuses on investing in cutting-edge technology, backing visionary entrepreneurs at the forefront of technological advancement.
What's next for Nucleai?
The substantial enterprise-level funding, including the recent major strategic investment, positions Nucleai for accelerated growth and expanded market penetration. This capital infusion is expected to fuel further development of its AI-driven oncology technology, enabling deeper exploration of cancer biology and the identification of novel therapeutic targets. The company's focus on enhancing clinical trial efficacy and patient outcomes suggests a strategic direction towards solidifying its role as a key partner for pharmaceutical companies in the oncology drug development pipeline. Future endeavors will likely involve scaling its platform's reach and impact within the precision medicine landscape.
See full Nucleai company page
